ERBB2 and melanoma: Retrospective analysis of CoBRIM clinical trial data shows that high MPAS correlates with improved progression-free survival (PFS) of vemurafenib-treated patients in BRAFV600E melanoma.9 Furthermore, we demonstrate that MPAS is associated with poor prognosis in adjuvant and metastatic colorectal cancer (CRC), adrenal cancers, and HER2-positive breast cancer.